First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers

计划入组 54 人 · 首次发布于 2017 年 7 月 21 日

Multiple Ascending Doses (MAD) of Anti-A Disintegrin and Metalloproteinase With Thrombospondin Motifs-5 (Anti-ADAMTS-5) Nanobody in Participants With Knee Osteoarthritis (OA)

计划入组 32 人 · 首次发布于 2018 年 7 月 11 日

ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).

计划入组 30 人 · 首次发布于 2014 年 10 月 21 日

5-Hydroxymethylfurfural

C₆H₆O₃

Recombinant ADAMTS-13 (Guangzhou Institutes of Biomedicine and Health)

5-iodotubercidin

C₁₁H₁₃IN₄O₄

Center 5

United States

Hangzhou MTR Line 5 Corporation Limited

China

INVESCO LDRRITE US 0-5 YR CO BD IDX CAD UNITS

FGF18 Emerges as Promising Therapeutic Target for Post-Traumatic Osteoarthritis Through FOXN2 Pathway

Eirion Therapeutics' ET-02 Shows Promise in Phase 1 Trial for Androgenic Alopecia

Paradigm's Zilosul Advances to Phase 3 Trial for Osteoarthritis Treatment in 2025